Research
Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone
Tony Antoniou, Simon Hollands, Erin M. Macdonald, Tara Gomes, Muhammad M. Mamdani and David N. Juurlink; for the Canadian Drug Safety and Effectiveness Research Network
CMAJ March 03, 2015 187 (4) E138-E143; DOI: https://doi.org/10.1503/cmaj.140816
Tony Antoniou
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
PhDSimon Hollands
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
MScErin M. Macdonald
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
MScTara Gomes
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
MHScMuhammad M. Mamdani
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
PharmD MPHDavid N. Juurlink
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
MD PhD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone
Tony Antoniou, Simon Hollands, Erin M. Macdonald, Tara Gomes, Muhammad M. Mamdani, David N. Juurlink
CMAJ Mar 2015, 187 (4) E138-E143; DOI: 10.1503/cmaj.140816
Jump to section
Related Articles
Cited By...
- Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
- Cotrimoxazole-induced hyperkalaemia in a patient with known hypoaldosteronism
- A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study
- Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation